Breast Cancer Research · 2010 · 51 citations · 28 references
MedicineCancer BiologyOncologyMolecular OncologyNeoplasiaOncogenesCancer BiomarkersCancer Cell SignalingCancer ProgressionMolecular Tumor ProfilingProtein Kinase CascadesTumor MarkersEstrogen Receptor StatusMolecular Prognostic MarkersPhosphatidylinositol 3-Kinase PathwayPhosphatidylinositol 3-Kinase-akt PathwayPrognostic Marker AssessmentPrognostic Molecular StratificationProtein Expression BiomarkersPten Inactivation
INTRODUCTION: Evaluating the expression of signaling molecule proteins from the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3-kinase (PI3K) pathway in invasive breast cancers may identify prognostic marker(s) associated with early relapse. METHODS: Immunohistochemical analyses of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), PI3K-p110alpha, phospho-AKT, phospho-p70S6 kinase, phospho-S6 ribosomal protein, phospho-RAF, phospho-p44/42 MAPK, and heat-shock protein 90 (HSP90) were performed on tumor samples from 212 patients with invasive breast cancer. Statistically significant relations between protein expression, clinicopathologic factors, and relapse-free survival (RFS) were analyzed. RESULTS: Expression of HSP90 was associated with 5-year RFS, as well as T stage, N stage, histologic grade, estrogen receptor (ER) expression, human epidermal growth factor receptor 2 (HER2) expression, and the Ki-67 proliferation index. On multivariate analysis, coexpression of HSP90 and PI3K-p110alpha or expression of HSP90 along with PTEN loss demonstrated significantly worse RFS. In subgroup analyses, both exhibited strong prognostic significance in HER2-positive cases, but not in HER2-negative cases. CONCLUSIONS: The coexpression of HSP90 with PI3K-p110alpha or expression of HSP90 along with PTEN loss has a potential as a molecular prognostic marker to predict early relapse in patients with invasive breast cancers.
28
Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science · 1987 · 11.7K citations
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
Adeela Kamal, Lia Thao, John Sensintaffar et al. · Nature · 2003 · 1.4K citations
Medicine, Oncology, Pharmacology +10